TY  - CONF
AU  - Bosch, Iris
AU  - Lenér, Frida
AU  - Stankeviciute, Laura
AU  - Singleton, Ellen Hanna
AU  - Öhman, Fredrik
AU  - Quitz, Kajsa
AU  - Dottori, Maria
AU  - Berron, David
AU  - Franzmeier, Nicolai
AU  - Kern, Silke
AU  - Zetterberg, Henrik
AU  - Blennow, Kaj
AU  - Schöll, Michael
TI  - From zero to 6,000 in 9 months: Recruitment and innovation strategies for a remote longitudinal Alzheimer's population‐based screening study – Insights from the REAL AD study
JO  - Alzheimer's and dementia
VL  - 21
IS  - Suppl 6
SN  - 1552-5260
M1  - DZNE-2025-01484
SP  - e106340
PY  - 2025
AB  - The REAL AD study aims to validate the diagnostic and prognostic performance of combining blood-based biomarkers and remote cognitive testing as a screening approach for early Alzheimer's disease (AD), leveraging an existing healthcare infrastructure in Western Sweden. Here, we discuss strategies for recruiting a large and representative cohort, demographics and participant retention during the first study phase, and evaluate the process of implementing innovations enabling a fully remote study design.In April 2024, a recruitment campaign was launched in collaboration with a PR company to recruit at least 3000 participants between 50-80 years from the general population. Through an online study platform, participants were enrolled and asked to answer health and lifestyle questionnaires (Step 1), guided to remotely administered cognitive testing (Step 2; using the neotivTrials app or Cognitron battery), and blood sampling at any of the 105 public regional primary care units (Step 3; Figure 1). Additionally, optional remote blood sampling complemented the primary study protocol.At abstract submission, N = 6092 participants (mean age=63.9 years, 70
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Humans
KW  - Female
KW  - Male
KW  - Aged
KW  - Middle Aged
KW  - Alzheimer Disease: diagnosis
KW  - Alzheimer Disease: blood
KW  - Public Health
KW  - Aged, 80 and over
KW  - Biomarkers: blood
KW  - Sweden
KW  - Neuropsychological Tests
KW  - Surveys and Questionnaires
KW  - Telemedicine
KW  - Patient Selection
KW  - Biomarkers (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
C6  - pmid:41435182
C2  - pmc:PMC12726296
DO  - DOI:10.1002/alz70860_106340
UR  - https://pub.dzne.de/record/283077
ER  -